Closer to an 'ideal inhaler' with the Easyhaler®: An innovative dry powder inhaler

Clinical Drug Investigation

Volumn 26, Issue 4, 2006, Pages 175-183

  Chrystyn, Henry ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; HYDROCORTISONE; SALBUTAMOL; TERBUTALINE;

ASTHMA; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRY POWDER; FLOW RATE; FORCED EXPIRATORY VOLUME; HUMAN; METERED DOSE INHALER; MULTIPLE DRUG DOSE; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

ADMINISTRATION, INHALATION; DRUG DELIVERY SYSTEMS; HUMANS; METERED DOSE INHALERS; PARTICLE SIZE; PATENTS; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; POWDERS;

EID: 33645534471     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626040-00001     Document Type: Review

References (40)

1. Paterson IC, Crompton GK. Use of pressurised aerosols by asthmatic patients. BMJ 1976; 1: 76-7
2. Crompton GK. Problems patients have using pressurised aerosol inhalers. Eur J Respir Dis Suppl 1982; 119: 101-4
3. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med 2000; 94: 496-500
4. Nimmo GJ, Chen DN, Martinusen SM, et al. Assessment of patient acceptance and inhalation technique of pressurized aerosol inhaler and two breath actuated devices. Ann Pharmacother 1993; 27: 922-7
5. Molina MJ, Rowland FS. Stratospheric sink for chlorofluromethanes: chlorine atom-catalysed destruction of ozone. Nature 1974; 249: 810-2
6. Noakes TJ. CFCs, their replacement and the ozone layer. J Aerosol Med 1995; 8 Suppl. 1: S3-7
7. United Nations Environmental Program (UNEP). Montreal Protocol on substances that deplete the Ozone Layer. Technology and Assessment Panel, Volumes I and II. Report Volumes I and II. The Netherlands: UNEP, 1997
8. Laursen LC. Clinical efficacy and safety of Turbuhaler as compared to pressurized MDIs-beta 2-agonists. J Aerosol Med 1994; 7 Suppl. 1: S59-62
9. Engel T, Heinig JH, Maling HJ, et al. Clinical comparison of inhaled budesonide delivered via pressurized metered dose inhaler or Turbuhaler. Allergy 1989; 44: 220-5
10. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide is twice that from a pressurized metered-dose inhaler pMDI. Eur Respir J 1994; 7: 1839-44
11. Vidgren P, Silvasti M, Poukkula A, et al. Easyhaler powder inhaler: a new alternative in the anti-inflammatory treatment of asthma. Acta Ther 1994; 20: 117-31
12. Chrystyn H. Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol 2001; 51: 289-99
13. Chrystyn H. Anatomy and physiology in delivery: can we define our targets? Allergy 1999; 54: 82-7
14. Cripps A, Riebe M, Schulze M, et al. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000; 94 Suppl. B: S3-9
15. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the in-check dial to identify these rates. Respir Med 2003; 97: 181-7
16. Cyr TD, Graham SJ, Li KY, et al. Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res 1991; 8 (5): 658-60
17. Graham SJ, Lawrence RC, Ormsby ED, et al. Particle size distribution of single and multiple sprays of salbutamol metered-dose inhalers (MDIs). Pharm Res 1995; 12 (9): 1380-4
18. LeBelle M, Pike RK, Graham SJ, et al. Metered-dose inhalers. I: drug content and particle size distribution of beclomethasone dipropionate. J Pharm Biomed Anal 1996; 14: 793-800
19. Cyr TD, Duhaime RM, Graham SJ, et al. Metered dose inhalers. III: metaproterenol sulphate; particle size distribution and dose uniformity. J Pharm Biomed Anal 1997; 15: 1709-18
20. Tarsin W, Assi KH, Chrystyn H. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J Aerosol Med 2004; 17: 25-32
21. Palander A, Mattila T, Karka M, et al. In vitro comparison of three salbutamol-containing multidose dry powder inhalers. Clin Drug Invest 2000; 20: 25-33
22. Chrystyn H, Corrado OJ, Brownlee K, et al. Inhalation rates of asthmatic children (CHILD) and adults and of chronic obstructive pulmonary disease (COPD) patients through inhalers. Am J Respir Crit Care Med 2002; 165: A190
23. Tarsin W, Hawksworth GM, Haslam GM, et al. Inter- and intravariability of inhalation rates when patients use their dry powder inhalers (DPI) [Abstract]. Thorax 2001; 56 Suppl. 3: 60
24. Tarsin WY, Assi KA, Pearson SB, et al. Ex-vivo emitted dose characterisation for combination formulations in dry powder inhalers (DPI) [Abstract]. Eur Respir J 2003; 22 Suppl. 45: 472s
25. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990; 65: 308-10
26. Nsour WM, Alldred A, Corrado OJ, et al. Measurement of peak inhalation rates with an In-Check Meter® to identify an elderly patient's ability to use a Turbuhaler®. Respir Med 2001; 95: 965-8
27. Malmstrom K, Sorva R, Silvasti M. Application and efficacy of the multi-dose dry powder inhaler, Easyhaler., in children with asthma. Pediatr Allergy Immunol 1999; 10: 66-70
28. Hirst PH, Bacon RE, Pitcairn GR, et al. A comparison of the lung deposition of budesonide from Easyhaler®, Turbuhaler® and pMDI plus spacer in asthmatic patients. Respir Med 2001; 95: 720-7
29. Koskela T, Malmstrom K, Sairanen U, et al. Efficacy of salbutamol via Easyhaler® unaffected by low inspiratory flow. Respir Med 2000; 94: 1229-33
30. Koskela T, Hedman J, Ekroos H, et al. Equivalence of two steroid-containing inhalers: Easyhaler multidose powder inhaler compared with conventional aerosol with large-volume spacer. Respiration 2000; 67: 194-202
31. Vidgren M, Silvasti M, Korhonen P, et al. Clinical equivalence of a novel multiple dose powder inhaler versus a conventional metered dose inhaler on bronchodilating effects of salbutamol. Drug Res 1995; 45: 44-7
32. Malinen A, Hedman J, Koskela T, et al. Salbutamol via Easyhaler® produces equivalent bronchodilation to terbutaline via Turbuhaler® following inhalation of a single dose of equipotent β2-sympathomimetic. Clin Drug Invest 2000; 20: 165-71
33. Vanto T, Hamalainen KM, Vahteristo M, et al. Comparison of two budesonide dry powder inhalers in the treatment of asthma in children. J Aerosol Med 2004; 17: 15-24
34. Schweisfurth H, Malinen A, Koskela T, et al. Comparison of two budesonide powder inhalers, Easyhaler® and Turbuhaler®, in steroid naive asthmatic patients. Respir Med 2002; 96: 599-606
35. Lahelma A, Kirjavainen M, Kela M, et al. Equivalent lung depostion of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. Br J Clin Pharmacol 2005 Feb; 59 (2): 167-73
36. Hamalainen KM, Granander M, Toivanen P, et al. Assessment of the systemic effects of budesonide inhaled from Easyhaler® and from Turbuhaler® in healthy male volunteers. Respir Med 2001; 95: 863-9
37. Tukiainen H, Rytila P, Hamalainen KM, et al. Safety, tolerability and acceptance of two dry powder inhalers in the administration of budesonide in steroid-treated asthmatic patients. Respir Med 2002; 96: 221-9
38. Rand CS, Wise RA. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 1994; 149: 69-76
39. Child F, Davies S, Clayton S, et al. Inhaler devices for asthma: do we follow the guidelines? Arch Dis Child 2002; 86: 176-9
40. Ahonen A, Leinonen M, Ranki-Pesonen M. Patient satisfaction with Easyhaler® compared with other inhalation systems in the treatment of asthma: a meta-analysis. Curr Ther Res Clin Exp 2000; 61: 61-73